Read the Latest News

Educational Brochures on Chronic Overlapping Pain Conditions

This brochure addresses what are Chronic Overlapping Pain Conditions (COPCs), how COPCs are diagnosed, the complexity of the chronic pain experience, and how to work with your health care provider to develop a treatment plan. It is available by postal ma

Study Highlights TMD Evidence and Current Practice Gaps

The TMJ Association has long championed the need for strong evidence-based demonstrations of the safety and efficacy of TMD diagnostics and treatments. Sad to say, as the following journal article indicates, even among a network of research-oriented practices, dental providers are still resorting to such TMD treatments as occlusal adjustments in which teeth are irreversibly moved, ground down, or in other ways altered, a treatment for which there is no scientific evidence of efficacy.

Beware of Ticks and Lyme Disease

We are currently in the peak season for Lyme disease. Each year at this time we highlight this topic because we have heard from a number of patients over the years who were misdiagnosed and underwent unnecessary TMD treatments when they actually had Lyme

#*!"@!**! ... May Help Your Pain... and Improve Strength!

Our headline is adopting the comic strip convention of using symbols to denote swear words because we are intrigued by a report that swearing may have some health benefits.

Predictors of Opioid Efficacy for Chronic Pain Patients

Opioids are increasingly used for treatment of chronic pain. However, they are only effective in a subset of patients and have multiple side effects. Thus, studies using biomarkers for response are highly warranted.

NIDCR Funds Consortium for Developing Dental and Orofacial Tissue Regeneration Therapies

  • May 31, 2017

The National Institute of Dental and Craniofacial Research (NIDCR) announced two new cooperative agreements aimed at developing resources and strategies for regenerating dental, oral, and craniofacial (DOC) tissues that have been damaged by disease or injury. Totaling $24 million over three years, these awards support the development of two Resource Centers as part of the NIDCR's Dental, Oral, and Craniofacial Tissue Regeneration Consortium (DOCTRC), an initiative designed to shepherd new therapies through pre-clinical studies and into human clinical trials. The ultimate goal is to develop strategies and devices that could help repair or regenerate damaged DOC tissues, including craniofacial bone, muscle and blood vessels, nerves, teeth, and salivary glands.

"By establishing this research consortium, NIDCR seeks to lead national efforts to accelerate the translation of promising DOC regenerative medicine therapies into the clinic," said NIDCR Director Martha J. Somerman, D.D.S., Ph.D. "DOCTRC is designed as a model for optimizing translation of scientific advances in this field."

To date, few DOC therapies based on regenerative medicine have been commercialized and reached the clinic. A careful analysis of NIDCR's research portfolio identified barriers to the process, and the DOCTRC was established to address them and build on the strength of existing research, using approaches such as:

  • Enhanced focus on clinical needs and involvement of practicing clinicians to inform the design of new therapies.
  • Development of approaches to generate multi-tissue composites rather than using a single tissue type.
  • Targeted translational research and early regulatory guidance.
  • Coordination among investigators and industry to develop, validate, and commercialize new tools and technologies.

DOCTRC is composed of three Stages. Stage 1, a one-year planning phase, was successfully completed in 2016. Among proposals submitted for Stage 2, two groups received awards to develop the Resource Centers over the next three years. The Centers will bring together clinical, scientific, industrial, and regulatory experts to develop an infrastructure to deliver high-quality support to Interdisciplinary Translational Projects to be launched during Stages 2 and 3. This support will entail development of standard assays, procedures, and study models to ensure that investigators can uniformly and reliably validate the technologies.

In Stage 3, the Resource Centers will collaborate with both internal and external investigators to move projects to the point of filing Investigational New Drug or Investigational Device Exemption (IND/IDE) applications with the U.S. Food and Drug Administration and launching human clinical trials.

"The DOCTRC consortium aims to streamline translation of dental, oral, and craniofacial regenerative therapies by leveraging multidisciplinary expertise to establish a systematic and uniform research process," said Nadya Lumelsky, Ph.D., Program Director of NIDCR's Tissue Engineering and Regenerative Medicine Research Program. "By establishing two national cores to support the regenerative medicine research community, DOCTRC represents a new paradigm in translational medicine."

The following RCs will be funded for up to three years:

Additional articles related to this announcement:
School of Dentistry Leads Major New Regenerative Medicine Center Funded by NIH

UCSF to Lead Resource Team for Craniofacial, Oral and Dental Tissue Regeneration

TMJ Disorders

Comments:

Login or Register to add Comment

In Treating TMJ

To view or order a free booklet about TMJ Disorders, visit the National Institutes of Health website.

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
National Institutes of Health
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health